Anatomy, Histology and Neuroscience Department, School of Medicine, Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain; Centro de Biología Molecular Severo Ochoa (UAM-CSIC), 28049, Madrid, Spain; Graduate Programa in Neuroscience, Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain.
Centro de Biología Molecular Severo Ochoa (UAM-CSIC), 28049, Madrid, Spain.
EBioMedicine. 2024 Feb;100:104953. doi: 10.1016/j.ebiom.2023.104953. Epub 2024 Jan 5.
Tau is a microtubule-binding protein encoded by the MAPT gene. Tau is essential for several physiological functions and associated with pathological processes, including Alzheimer's disease (AD). Six tau isoforms are typically described in the central nervous system, but current research paints a more diverse landscape and a more nuanced balance between isoforms. Recent work has described tau isoforms generated by intron 11 and intron 12 retention. This work adds to that evidence, proving the existence of MAPT transcripts retaining intron 3. Our aim is to demonstrate the existence of mature MAPT RNA species that retain intron 3 in human brain samples and to study its correlation with Alzheimer's disease across different regions.
Initial evidence of intron-3-retaining MAPT species come from in silico analysis of RNA-seq databases. We further demonstrate the existence of these mature RNA species in a human neuroepithelioma cell line and human brain samples by quantitative PCR. We also use digital droplet PCR to demonstrate the existence of RNA species that retain either intron 3, intron 12 or both introns.
Intron-3-retaining species are even more prominently present that intron-12-retaining ones. We show the presence of MAPT transcripts that retain both introns 3 and 12. These intron-retaining species are diminished in brain samples of patients with Alzheimer's disease with respect to individuals without dementia. Conversely, relative abundance of intron-3- or intron-12-retaining MAPT species with respect to double-retaining species as well as their percentage of expression with respect to total MAPT are increased in patients with Alzheimer's disease, especially in hippocampal samples. Among these TIR-MAPT species, TIR double truncation allows better classification potential of Alzheimer's disease samples. Moreover, we find a significant increase in intron-3- or intron-12-retaining species and its relative abundance with respect to double-retaining MAPT species in cerebellum in contrast to frontal lateral cortex and hippocampus in individuals with no signs of dementia.
Intron retention constitutes a potential mechanism to generate Tau isoforms whose mature RNA expression levels correlate with Alzheimer's pathology showing its potential as a biomarker associated to the disease.
This research was funded by the Spanish Ministry of Science, Innovation and Universities: PGC2018-096177-B-I00 (J.A.); Spanish Ministry of Science and Innovation (MCIN): PID2020-113204GB-I00 (F.H.) and PID2021-123859OB-100 from MCIN/AEI/10.13039/501100011033/FEDER, UE (J.A.). It was also supported by CSIC through an intramural grant (201920E104) (J.A.) and the Centre for Networked Biomedical Research on Neurodegenerative Diseases (J.A.). The Centro de Biología Molecular Severo Ochoa (CBMSO) is a Severo Ochoa Center of Excellence (MICIN, award CEX2021-001154-S).
Tau 是由 MAPT 基因编码的微管结合蛋白。Tau 在包括阿尔茨海默病(AD)在内的几种生理功能和病理过程中是必不可少的。中枢神经系统中通常描述了六种 Tau 同工型,但目前的研究描绘了一个更加多样化的图景,以及同工型之间更加微妙的平衡。最近的工作描述了通过内含子 11 和内含子 12 保留产生的 Tau 同工型。这项工作增加了证据,证明存在保留内含子 3 的 MAPT 转录本。我们的目的是证明在人类脑组织样本中存在保留内含子 3 的成熟 MAPT RNA 物种,并研究其在不同区域与阿尔茨海默病的相关性。
内含子 3 保留的 MAPT 物种的最初证据来自于 RNA-seq 数据库的计算机分析。我们通过定量 PCR 进一步证明了这些成熟 RNA 物种在人类神经上皮细胞瘤系和人类脑组织样本中的存在。我们还使用数字液滴 PCR 来证明存在保留内含子 3、内含子 12 或两者的 RNA 物种。
内含子 3 保留的物种比内含子 12 保留的物种更为明显。我们展示了保留内含子 3 和 12 的 MAPT 转录本的存在。与无痴呆症患者的脑组织样本相比,这些内含子保留的物种在阿尔茨海默病患者中减少。相反,与双内含子保留的 MAPT 物种相比,内含子 3 或内含子 12 保留的 MAPT 物种的相对丰度以及其相对于总 MAPT 的表达百分比在阿尔茨海默病患者中增加,尤其是在海马体样本中。在这些 TIR-MAPT 物种中,TIR 双截断允许更好地对阿尔茨海默病样本进行分类。此外,我们发现与额外侧皮质和海马体相比,在无痴呆症个体的小脑组织中,保留内含子 3 或内含子 12 的物种及其相对于双保留 MAPT 物种的相对丰度显著增加。
内含子保留构成了产生 Tau 同工型的潜在机制,其成熟 RNA 表达水平与阿尔茨海默病病理相关,显示其作为与该疾病相关的生物标志物的潜力。
这项研究得到了西班牙科学、创新和大学部的资助:PGC2018-096177-B-I00(J.A.);西班牙科学和创新部(MCIN):PID2020-113204GB-I00(F.H.)和 PID2021-123859OB-100 来自 MCIN/AEI/10.13039/501100011033/FEDER,欧盟(J.A.)。它还得到了 CSIC 通过一项内部拨款(201920E104)(J.A.)和神经退行性疾病网络生物医学研究中心(J.A.)的支持。塞维罗·奥乔亚分子生物学中心(CBMSO)是塞维罗·奥乔亚卓越中心(MICIN,奖项 CEX2021-001154-S)。